PUB - Publikationen an der Universität Bielefeld

Alle markieren

• [55]
  

  2023 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2988304

  R.M. Seifert, et al., “Case report: Cerebral amyloid angiopathy-related inflammation in a patient with granulomatosis with polyangiitis”, Frontiers in Neurology, vol. 14, 2023.

  PUB | PDF | DOI
   
• [54]
  

  2023 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2985913

  M. Rudwaleit, et al., “Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis”, RMD Open, vol. 9, 2023, : e003468.

  PUB | PDF | DOI | Download (ext.) | WoS | PubMed | Europe PMC
   
• [53]
  

  2023 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2984077

  C. Löffler, et al., “Patient-reported-Outcomes bei Vaskulitispatienten in Deutschland – Daten aus dem KOBRA-Qualitätsprojekt”, Zeitschrift für Rheumatologie, 2023.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [52]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987167

  M. Rudwaleit, et al., “LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 614-615.

  PUB | DOI | WoS
   
• [51]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987166

  M. Rudwaleit, et al., “AN EXPLORATORY ANALYSIS OF THE POTENTIAL DISCONNECT BETWEEN OBJECTIVE INFLAMMATORY RESPONSE AND CLINICAL RESPONSE FOLLOWING CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 624-625.

  PUB | DOI | WoS
   
• [50]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987165

  X. Baraliakos, et al., “COMPARISON OF ESTABLISHED AND NEW, PRELIMINARY PROPOSED ASAS CUT-OFFS FOR INFLAMMATORY MRI LESIONS IN THE SACROILIAC JOINTS OF AXIAL SPONDYLOARTHRITIS PATIENTS AND IMPLICATIONS FOR RECRUITMENT IN CLINICAL STUDIES”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 621-622.

  PUB | DOI | WoS
   
• [49]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987161

  M. Torgutalp, et al., “FACTORS ASSOCIATED WITH ACHIEVING REMISSION IN PATIENTS WITH EARLY PERIPHERAL SPONDYLOARTHRITIS: 10-YEAR RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT (GESPIC)”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 37-38.

  PUB | DOI | WoS
   
• [48]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987156

  J.F. Schmidt, et al., “QUALITY STANDARDS FOR PATIENTS WITH AXSPA - STATUS QUO OF DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF AXSPA PATIENTS IN GERMANY”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 1713.

  PUB | DOI | WoS
   
• [47]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2980346

  M. Röchter, et al., “Changes in diagnosing giant cell arteritis of the temporal artery over a 7.7 year period”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 1579.

  PUB | DOI | WoS
   
• [46]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987168

  X. Baraliakos, et al., “ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 875-876.

  PUB | DOI | WoS
   
• [45]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987172

  K. Albrecht, et al., “IMPLEMENTATION OF QUALITY STANDARDS FOR HEALTH CARE OF PATIENTS WITH RHEUMATOID ARTHRITIS: FIRST RESULTS FROM THE NATIONAL DATABASE OF THE GERMAN COLLABORATIVE ARTHRITIS CENTRES”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 868-869.

  PUB | DOI | WoS
   
• [44]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987170

  M. Magrey, et al., “ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 1721.

  PUB | DOI | WoS
   
• [43]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987174

  V. Navarro-Compán, et al., “ASAS CONSENSUS DEFINITION OF EARLY AXIAL SPONDYLOARTHRITIS”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 35-36.

  PUB | DOI | WoS
   
• [42]
  

  2023 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2986690

  F.A. van Gaalen and M. Rudwaleit, “Challenges in the diagnosis of axial spondyloarthritis”, Best Practice & Research Clinical Rheumatology, vol. 37, 2023, : 101871.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [41]
  

  2023 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2985592

  J. Braun, M. Rudwaleit, and J. Sieper, “Zur Rolle von HLA-B27 in der Pathogenese und Diagnostik der axialen Spondyloarthritis. 50 Jahre nach Entdeckung der starken genetischen Assoziation”, Zeitschrift fur Rheumatologie, 2023.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [40]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2983818

  X. Baraliakos, et al., “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2”, Abstracts of the Annual meeting of theSwiss Society of Rheumatology, Swiss Medical Weekly, vol. 153, Basel: EMH Schweizerischer Ärzteverlag, 2023, pp.23S.

  PUB | DOI | WoS
   
• [39]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2984578

  X. Baraliakos, et al., “Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2”, Abstract Supplement - 39th Scandinavian Congress of Rheumatology, Scandinavian Journal of Rheumatology , vol. 52, Abingdon: Taylor & Francis , 2023, pp.73-74.

  PUB | DOI | WoS
   
• [38]
  

  2023 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2982993

  M. Rudwaleit, et al., “Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis”, Therapeutic Advances in Musculoskeletal Disease , vol. 15, 2023.

  PUB | DOI | PubMed | Europe PMC
   
• [37]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2982790

  J. Zochling, et al., “Long-term clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis stratified by baseline MRI and c-reactive protein status”, Internal Medicine Journal, vol. 53, 2023, pp. 25.

  PUB | DOI | WoS
   
• [36]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2982783

  M. Rudwaleit, et al., “Systematic Literature Review and Meta-Analysis of Work Productivity in Patients with Axial Spondyloarthritis Treated with Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs”, Value in Health, vol. 26, 2023, pp. S397.

  PUB | DOI | WoS
   
• [35]
  

  2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2982796

  P. Bird, et al., “Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies”, Internal Medicine Journal, vol. 53, 2023, pp. 24-25.

  PUB | WoS
   
• [34]
  

  2023 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2968910

  J. Braun, et al., “Nachruf der Deutschen Gesellschaft für Rheumatologie (DGRh) auf den Träger der Kussmaul-Medaille der DGRh Prof. Dr. Ernst Feldtkeller”, Zeitschrift für Rheumatologie, 2023.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [33]
  

  2023 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2968373

  M.-H. Röchter and M. Rudwaleit, “Phänomen der letzten Wiese”, Zeitschrift fur Rheumatologie, 2023.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [32]
  

  2023 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2968388

  D. van der Heijde, et al., “Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials”, Annals of the Rheumatic Diseases, 2023.

  PUB | PDF | DOI | Download (ext.) | WoS | PubMed | Europe PMC
   
• [31]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2969537

  M. Magrey, et al., “Association of Clinical Response Criteria and Disease Activity Levels With Physical Function and HRQoL in Patients With Active Axial Spondyloarthritis: 16-Week Results From Two Phase 3 Randomised, Placebo-Controlled Studies”, ISPOR Europe 2022 Abstracts, Value in Health, vol. 25, New York: Elsevier , 2022, pp.S427-S428.

  PUB | DOI | WoS
   
• [30]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968210

  M. Torgutalp, et al., “Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.2946-2948.

  PUB | DOI | WoS
   
• [29]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968211

  X. Baraliakos, et al., “Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.1997-2000.

  PUB | DOI | WoS
   
• [28]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968213

  J. Brandt-Juergens, et al., “Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.2074-2076.

  PUB | DOI | WoS
   
• [27]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968219

  A. Deodhar, et al., “Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.1101-1105.

  PUB | DOI | WoS
   
• [26]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968220

  T. Diekhoff, et al., “ASAS Recommendations for Requesting and Reporting Imaging in Patients with Suspected Axial Spondyloarthritis”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Reumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.788-790.

  PUB | DOI | WoS
   
• [25]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968222

  S. Ramiro, et al., “ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update”, ABSTRACT SUPPLEMENT ACR Convergence 2022 ,November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.1094-1097.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [24]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968218

  P.J. Mease, et al., “Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatolgy, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.810-813.

  PUB | DOI | WoS
   
• [23]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968217

  W.P. Maksymowych, et al., “MRI Spinal Lesions in Patients Without MRI or Radiographic Lesions in the Sacroiliac Joints Typical of Axial Spondyloarthritis”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.4490-4492.

  PUB | DOI | WoS
   
• [22]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968216

  M. Magrey, et al., “Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.814-816.

  PUB | DOI | WoS
   
• [21]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968215

  M. Rudwaleit, et al., “An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.1097-1100.

  PUB | DOI | WoS
   
• [20]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2968214

  P.C. Robinson, et al., “Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.808-810.

  PUB | DOI | WoS
   
• [19]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2966738

  V. Navarro-Compan, et al., “MAINTENANCE OF RESPONSE TO BIMEKIZUMAB OVER 3 YEARS OF TREATMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POST HOC ANALYSES FROM THE BE AGILE STUDY AND ITS OPEN-LABEL EXTENSION”, Annals of the Rheumatic Diseases, vol. 81, 2022, pp. 771-772.

  PUB | DOI | WoS
   
• [18]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2966741

  M. Torgutalp, et al., “TREATMENT WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IS ASSOCIATED WITH RETARDATION OF RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 10-YEAR RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT”, Annals of the Rheumatic Diseases, vol. 81, London: Bmj Publishing Group, 2022, pp.14-15.

  PUB | DOI | WoS
   
• [17]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2966746

  P. Robinson, et al., “LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS”, Annals of the Rheumatic Diseases, vol. 81, London: Bmj Publishing Group, 2022, pp.774-775.

  PUB | DOI | WoS
   
• [16]
  

  2022 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2966748

  A. Deodhar, et al., “BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY”, Annals of the Rheumatic Diseases, vol. 81, London: Bmj Publishing Group, 2022, pp.772-773.

  PUB | DOI | WoS
   
• [15]
  

  2022 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2965259

  M. Torgutalp, et al., “Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort”, Arthritis & Rheumatology , 2022.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [14]
  

  2022 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2963951

  M. Torgutalp, et al., “Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis”, Annals of the rheumatic diseases, vol. 81, 2022, pp. 1252-1259.

  PUB | PDF | DOI | Download (ext.) | WoS | PubMed | Europe PMC
   
• [13]
  

  2022 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2964357

  P.C. Robinson, et al., “Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study”, ACR Open Rheumatology, 2022.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [12]
  

  2022 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2963700

  X. Baraliakos, et al., “MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group”, Annals of the Rheumatic Diseases, 2022.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [11]
  

  2022 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2962214

  D. van der Heijde, et al., “Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study”, RMD Open, vol. 8, 2022, : e002138.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [10]
  

  2021 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2961894

  X. Baraliakos, et al., “Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time?”, Abstract Supplement ACR Convergence 2021 , American College of Rheumatology, ed., Arthritis & Rheumatology , vol. 73, Hoboken: Wiley, 2021, pp.319-321.

  PUB | DOI | WoS
   
• [9]
  

  2021 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2961900

  W. Maksymowych, et al., “Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis”, Abstract Supplement ACR Convergence 2021, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 73, Hoboken: Wiley, 2021, pp.1878-1880.

  PUB | DOI | WoS
   
• [8]
  

  2021 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2961899

  W. Maksymowych, et al., “Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal?”, Abstract Supplement ACR Convergence 2021, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 73, Hoboken: Wiley, 2021, pp.1876-1878.

  PUB | DOI | WoS
   
• [7]
  

  2021 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2961897

  D. van der Heijde, et al., “Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study”, Abstract Supplement ACR Convergence 2021, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 73, Hoboken: Wiley, 2021, pp.1896-1899.

  PUB | DOI | WoS
   
• [6]
  

  2021 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2961896

  M. Magrey, et al., “Predictors of 1-Year Treatment Response Among Upadacitinib-Treated Patients with Ankylosing Spondylitis: A Post Hoc Analysis”, Abstract Supplement ACR Convergence 2021 , American College of Rheumatology, ed., Arthritis & Rheumatology , vol. 73, Hoboken: Wiley, 2021, pp.1931-1933.

  PUB | DOI | WoS
   
• [5]
  

  2021 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2961895

  M. Rudwaleit, et al., “Achievement of Stringent Thresholds of Disease Control Is Associated with Reduced Burden on Work and Household Productivity in Patients with Axial Spondyloarthritis”, Abstract Supplement ACR Convergence 2021 , American College of Rheumatology, ed., Arthritis & Rheumatology , vol. 73, Hoboken: Wiley, 2021, pp.734-738.

  PUB | DOI | WoS
   
• [4]
  

  2021 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2961892

  M. Torgutalp, et al., “Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort”, Abstract Supplement ACR Convergence 2021 , American College of Rheumatology, ed., Arthritis & Rheumatology , vol. 73, Hoboken: Wiley, 2021, pp.931-933.

  PUB | DOI | WoS
   
• [3]
  

  2021 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2961881

  L.E. Kristensen, et al., “Association of the improvement of Synovitis and Enthesitis with quality of life/patient reported outcomes in patients with PsA treated with Ixekizumab”, Abstract Supplement ACR Convergence 2021 , American College of Rheumatology, ed., Arthritis & Rheumatology , vol. 73, Hoboken: Wiley, 2021, pp.3722-3724.

  PUB | DOI | WoS
   
• [2]
  

  2021 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2959486

  W.P. Maksymowych, et al., “Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol”, Arthritis Research and Therapy , vol. 23, 2021, : 274.

  PUB | DOI | WoS | PubMed | Europe PMC
   
• [1]
  

  2021 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2958359

  U. Kiltz, et al., “Entwicklung von Qualitätsstandards für die Versorgung von Patient*innen mit rheumatoider Arthritis zur Anwendung in Deutschland”, Zeitschrift fur Rheumatologie, 2021.

  PUB | DOI | WoS | PubMed | Europe PMC